NCT03809702

Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia

Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia and for the Prevention of Post Herpetic Neuralgia- a Randomized Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: B.P. Koirala Institute of Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

All eligible Herpes Zoster patients will be randomized into two groups. Group 1 will be the treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other routine treatment. Whereas, group 2 will be the control group receiving all routine treatment similar to group 1 except Pregabalin. Instead control group will receive Placebo.

Detailed description

This study wants to see the role of Pregabalin in acute herpetic neuralgia pain reduction and for the prevention of post herpetic neuralgia incidence as compared to placebo group. For this purpose, all eligible Herpes Zoster patients will be randomized into two groups (41 patients in each group i.e.82 total patients). Group 1 will be the treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other routine treatment. Whereas, group 2 will be the control group receiving all routine treatment similar to group 1 except Pregabalin. Instead of pregabalin, control group will receive Placebo. The pain will be evaluated in all patients in each follow visits (weekly follow up for 4 weeks then monthly follow up for next three months). If it is difficult for the patient to present physically, telephonic follow up will be done to find the pain score in the required time. Also, DLQI (Dermatological life quality index) will be assessed at the first and last visit of the patient. At the end, pain score will be compared between the two groups.

Conditions

• Herpes Zoster

Interventions

Type	Name	Description
DRUG	Pregabalin	Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
DRUG	Placebo	Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)

Timeline

• Start date: 2018-07-15
• Primary completion: 2019-09-20
• Completion: 2019-12-30
• First posted: 2019-01-18
• Last updated: 2020-10-14

Locations

1 site across 1 country: Nepal